UCB expands autoimmune pipeline with US$2.2B Candid Therapeutics acquisition

USA—Global biopharmaceutical company UCB has signed a definitive agreement to acquire clinical-stage biotech firm Candid Therapeutics in a deal worth up to US$2.2 billion, strengthening its position in the rapidly evolving market for autoimmune and inflammatory disease treatments.

The transaction includes an upfront payment of US$2 billion, with an additional US$200 million tied to future milestone achievements.

The acquisition is expected to close by the end of the second quarter or early third quarter of 2026, pending regulatory approvals and customary closing conditions.

The move comes just weeks after UCB announced its acquisition of Neurona Therapeutics and follows its recent licensing agreement with Antengene, highlighting the company’s aggressive expansion strategy across immunology and neuroscience.

Analysts say these back-to-back deals reflect UCB’s broader effort to diversify its pipeline through external innovation while maintaining its long-term growth outlook.

Cizutamig takes center stage

At the heart of the acquisition is cizutamig, Candid’s lead investigational therapy and a bispecific antibody designed to target B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells.

This mechanism enables T-cell-directed destruction of pathogenic plasma cells and B-cells that drive several autoimmune disorders.

Cizutamig has already been evaluated in more than 100 patients across multiple myeloma and autoimmune disease studies.

It is currently being assessed in several early-stage clinical trials spanning more than 10 autoimmune indications.

Early data suggest the therapy may achieve deep immune cell depletion while limiting cytokine release syndrome, a common safety concern with T-cell engager therapies.

Industry observers view this as a potentially important step toward achieving what researchers describe as “immune reset” in severe autoimmune diseases.

UCB Chief Executive Officer Jean-Christophe Tellier described the acquisition as a pivotal milestone for the company’s immunology strategy, noting that cizutamig could become a transformative treatment option for patients with severe immune-mediated diseases.

Building a broader autoimmune platform

Beyond cizutamig, Candid brings a broader portfolio of multi-specific T-cell engager antibodies designed to selectively eliminate pathogenic B-cell populations.

These therapies use a modular multi-antigen targeting strategy that could support deeper and more durable disease control.

Candid Chairman and CEO Dr. Ken Song said the company built its pipeline to redefine care standards in immune-mediated diseases and emphasized that UCB’s commercial and development expertise will accelerate ongoing clinical programs.

UCB said the acquisition will not alter its 2026 financial guidance, with the company still projecting high single-digit to low double-digit revenue growth for the year as it continues investing in next-generation biologics.

Cizutamig remains investigational and has not yet received approval from the U.S. Food and Drug Administration or other health regulators.